Biogen partner sues over $1.5b J&J agreement
A partnership between the Irish drug maker Elan Corp. and Cambridge biotechnology company Biogen Idec Inc. has turned into a legal battle over a multiple sclerosis drug, Tysabri. (Full article: 405 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
